FR2724846B1 - Methode de traitement des cancers par regulation de l'activite des proteines ras - Google Patents

Methode de traitement des cancers par regulation de l'activite des proteines ras

Info

Publication number
FR2724846B1
FR2724846B1 FR9411510A FR9411510A FR2724846B1 FR 2724846 B1 FR2724846 B1 FR 2724846B1 FR 9411510 A FR9411510 A FR 9411510A FR 9411510 A FR9411510 A FR 9411510A FR 2724846 B1 FR2724846 B1 FR 2724846B1
Authority
FR
France
Prior art keywords
regulating
activity
treating cancer
ras proteins
ras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9411510A
Other languages
English (en)
Other versions
FR2724846A1 (fr
Inventor
Bruno Tocque
Bohdan Wasylyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Priority to FR9411510A priority Critical patent/FR2724846B1/fr
Priority to AU35249/95A priority patent/AU3524995A/en
Priority to PCT/FR1995/001227 priority patent/WO1996010087A1/fr
Publication of FR2724846A1 publication Critical patent/FR2724846A1/fr
Application granted granted Critical
Publication of FR2724846B1 publication Critical patent/FR2724846B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR9411510A 1994-09-27 1994-09-27 Methode de traitement des cancers par regulation de l'activite des proteines ras Expired - Fee Related FR2724846B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR9411510A FR2724846B1 (fr) 1994-09-27 1994-09-27 Methode de traitement des cancers par regulation de l'activite des proteines ras
AU35249/95A AU3524995A (en) 1994-09-27 1995-09-22 Method for treatment of cancers by regulating the activity of ras proteins
PCT/FR1995/001227 WO1996010087A1 (fr) 1994-09-27 1995-09-22 Methode de traitement des cancers par regulation de l'activite des proteines ras

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9411510A FR2724846B1 (fr) 1994-09-27 1994-09-27 Methode de traitement des cancers par regulation de l'activite des proteines ras

Publications (2)

Publication Number Publication Date
FR2724846A1 FR2724846A1 (fr) 1996-03-29
FR2724846B1 true FR2724846B1 (fr) 1996-12-20

Family

ID=9467309

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9411510A Expired - Fee Related FR2724846B1 (fr) 1994-09-27 1994-09-27 Methode de traitement des cancers par regulation de l'activite des proteines ras

Country Status (3)

Country Link
AU (1) AU3524995A (fr)
FR (1) FR2724846B1 (fr)
WO (1) WO1996010087A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6248351B1 (en) 1997-01-10 2001-06-19 Board Of Regents,The University Of Texas System Human PEA3 is a tumor suppressor for cancer cells
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1330271A4 (fr) * 2000-09-20 2005-11-09 Beth Israel Hospital Utilisation de facteurs de transcription dans le traitement d'inflammation et d'autres maladies
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US20050260582A1 (en) * 2001-02-13 2005-11-24 Hirofumi Kai Cell proliferation inhibitors comprising ets transcription factor or gene encoding the same
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren

Also Published As

Publication number Publication date
WO1996010087A1 (fr) 1996-04-04
AU3524995A (en) 1996-04-19
FR2724846A1 (fr) 1996-03-29

Similar Documents

Publication Publication Date Title
FR18C1021I2 (fr) Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
FR2724846B1 (fr) Methode de traitement des cancers par regulation de l'activite des proteines ras
FR10C0016I2 (fr) Procedes et compositions s'appliquant au traitement de la glomerulonephrite
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
FI962557A0 (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
FI971956A0 (fi) Hermosolujen lisääntymisen säännöstely
DE69609868D1 (de) Neue steroidester zur behandlung von hauterkrankungen
DE69510696D1 (de) 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)-benzopyran für die behandlung von proliferativer erkrankungen
ATE231724T1 (de) Kombinationstherapie für die behandlung von psychosen
FR2739255B1 (fr) Composition antiparasitaire pour le traitement et la protection des animaux de compagnie
FI943625A (fi) Menetelmiä tulehduksellisten ihotautien hoitamiseksi
DE69618188D1 (de) Kosmetisches hautbehandlungsverfahren
FR2723697B1 (fr) Methode de traitement de la restenose par la therapie genique
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
FI974640A0 (fi) Migreenin hoitoon tarkoitetut 1,6-disubstituoidut isokromaanit
DE69729004D1 (de) Photodynamische therapie zur behandlung von osteosrthritis
FR2732191B1 (fr) Procede de traitement antifongique des bananiers
ES2110550T3 (es) Tratamiento de la carne o del pescado.
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
NO981822L (no) Anvendelse av proteinet GAX for behandling av cancer
EE9700235A (et) Benseenamiidid neurodegeneratiivsete haiguste ravimiseks
FR2674844B1 (fr) Procede et installation de traitement d'epuration de lisiers d'animaux.
FR2720277B1 (fr) Méthode de traitement des cancers par régulation de la protéine P53.
FR2719240B1 (fr) Procédé de traitement des suspensions huileuses.

Legal Events

Date Code Title Description
ST Notification of lapse